Neovacs S.A. risk profile
53 Elevated one input has moved against it
Measured 10 September 2026 from 0LW0's filed statements. Recomputed nightly.
53 (Elevated), driven by Cash conversion at 100, over 4 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | Reads pct_below_52w_high, volatility_1y_pct and avg_turnover_90d_usd. No reading is stored for this company. | |||
| Operating pressure | 44 | Elevated | Worsening | Costs outgrowing revenue — +40.7 percentage points |
| Cash conversion | 100 | Acute | Stable | Capital spending against operating cash — -0.02x |
| Leverage and coverage | 19 | Contained | Worsening | Current ratio — 0.63x |
| Competitive position | 56 | Elevated | Stable | Operating-margin gap against peers — -3,502.0 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.